BOTHELL, Wash., Oct. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the three- and nine-month periods ended September 30, 2007.
Revenue for the quarter ended September 30, 2007 was $1.9 million, compared to $5.5 million for the quarter ended September 30, 2006. The 2006 period included revenue of $4.8 million related to our Parathyroid Hormone (PTH1-34) nasal spray collaboration with Procter & Gamble Pharmaceuticals, Inc. ("P&G"). Revenue for the nine months ended September 30, 2007 was $11.7 million, compared to $23.7 million for the nine months ended September 30, 2006. The 2007 period included receipt and recognition of a $2.0 million payment from QOL Medical LLC related to the June 2007 issuance of a patent by the U.S. Patent and Trademark Office for Nascobal(R) nasal spray, and revenue recognized related to our collaboration agreement with P&G, revenue from our other agreements including Novo Nordisk A/S and Amylin Pharmaceuticals, Inc. and approximately $0.2 million in Nascobal(R) product revenue. The prior year nine month period included recognition of approximately $3.7 million in previously deferred revenue from Merck & Co., Inc. related to our PYY(3-36) obesity program, a $7.0 million milestone payment and reimbursement revenue related to our development agreement with P&G, revenue from other agreements and approximately $0.6 million in Nascobal(R) product revenue.
Net loss for the current quarter was $16.5 million, or $0.66 per share, as compared to a net loss of $7.8 million, or $0.36 per share for the prior year period. The net loss for the nine months ended September 30, 2007 was $40.4 million or $1.62 per share, as compared to $16.2 million, or $0.77 per share, for the prior year period. The increase in the net loss from the prior year periods is due to a combination of lower revenue and higher spending due to increased clinical activities, headcount growth, and expenses related to research and development projects. The net loss for the prior year nine month period includes a cumulative benefit from the accounting change of adopting SFAS123(R) in January 2006 of approximately $0.3 million reflecting the net cumulative impact of estimating future forfeitures in the determination of period expense for restricted stock awards, rather than recording forfeitures when they occur as permitted prior to 2006.
Research and development expenses for the current quarter increased $3.3 million to approximately $13.8 million as compared to the prior year period and increased $8.4 million to $39.4 million for the nine months ended September 30, 2007 from the prior year period. This year-to-date net increase reflects an actual increase of approximately $12.5 million in R&D expenditures, primarily due to increases in clinical activities, the number of research and development employees and related infrastructure costs. The prior year nine month period included a $4.1 million charge due to in-process R&D expenses related to our acquisition of RNAi intellectual property from Galenea Corp. in the first quarter 2006.
Selling, general and administrative expenses increased $1.6 million to approximately $5.1 million for the current quarter compared to the prior year quarter and increased $4.0 million to approximately $14.5 million for the nine months ended September 30, 2007 from the prior year period, primarily due to increases in patent and legal costs necessary to support our business model as well as our growth.
We ended the third quarter of 2007 with approximately $58.1 million in cash, cash equivalents and investments compared to $51.0 million at December 31, 2006, including $2.2 million in restricted cash at each date. The increase in our cash balance was driven by the January 2007 offering of common stock which raised net proceeds of approximately $40.9 million.
Recent Corporate Highlights
* Initiated a Phase 2 clinical trial for PYY(3-36) Nasal Spray for
* Initiated a Phase 2 clinical trial for Insulin Nasal Spray for diabetes
* Announced promotion of Henry "Rick" Costantino to Chief Scientific
Officer of Delivery
Conference Call and Webcast Information
Management will host a conference call to review our financial results for the period ended September 30, 2007 and recent business developments. The call is scheduled for today, October 29, 2007, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). To participate in the live conference call, U.S. residents should dial (866) 831-6243 and international callers should dial (617) 213- 8855. The access code for the live conference call is 60453924. To access the 24-hour telephone replay, U.S. residents should dial (888) 286-8010 and international callers should dial (617) 801-6888. The access code for the replay is 53042322.
Alternatively, log on to http://www.nastech.com to access a live webcast or the subsequent archive. Please connect to the Investor section of Nastech's website several minutes prior to the start of the live conference call to ensure adequate time for any software download that may be necessary.
Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
Nastech Forward-Looking Statements
Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Director, Investor Relations
Russo Partners, LLC
David Schull (Media)
NASTECH PHARMACEUTICAL COMPANY INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
Three Months Ended Nine Months Ended
September 30, September 30,
2006 2007 2006 2007
License and research fees $ 5,130 $ 1,792 $ 22,667 $ 11,197
Government grants 383 105 383 307
Product revenue 32 -- 624 245
Total revenue 5,545 1,897 23,674 11,749
Cost of product revenue 13 -- 314 68
Research and development 10,483 13,774 31,050 39,412
Selling, general and
administrative 3,447 5,090 10,529 14,490
Total operating expenses 13,943 18,864 41,893 53,970
Loss from operations (8,398) (16,967) (18,219) (42,221)
Other income (expense):
Interest income 751 817 2,107 2,722
Interest and other expense (161) (300) (394) (858)
Loss before cumulative effect of (7,808) (16,450) (16,506) (40,357)
change in accounting principle
Cumulative effect of change in
accounting principle -- -- 291 --
Net Loss $(7,808) $(16,450) $(16,215) $(40,357)
Basic and diluted net loss per
Prior to cumulative effect of
change in accounting
principle $ (0.36) $ (0.66) $ (0.78) $ (1.62)
Cumulative effect of change in
accounting principle -- -- 0.01 --
Net loss per common share -
basic and diluted $ (0.36) $ (0.66) $ (0.77) $ (1.62)
Shares used in computing net
loss per share - basic and
diluted 21,408 25,067 21,115 24,844
Selected Balance Sheet Data (In Thousands) December 31, September 30,
Cash, cash equivalents and investments
(includes restricted cash of
approximately $2,155) $ 50,993 $ 58,139
Accounts receivable, net 2,798 124
Property and equipment, inventories and
other assets 20,041 20,156
Total assets 73,832 78,419
Working capital 42,833 43,777
Accumulated deficit (142,493) (182,850)
Stockholders' equity 43,336 49,743
|SOURCE Nastech Pharmaceutical Company Inc.|
Copyright©2007 PR Newswire.
All rights reserved